Compare The Coca-Cola Co K (KO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Sanofi SA — how do they compare? The Coca-Cola Co K trades at $88.4 (market cap $377.63B), while Sanofi SA trades at $40.13 (market cap $95.18B). The key difference: The Coca-Cola Co K is far larger — about 4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Sanofi SA for 94 Days on average.
| KO | SNY | |
|---|---|---|
Market Cap | $377.63B | $95.18B |
Volume | 14,894,568 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $52.34 |
52-Week Low | $66.37 | $39.51 |
Typical Hold Time | 154 Days | 94 Days |
Enterprise Value | $404.81B | $114.48B |
Dividend Yield | 2.42% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.97, up 2.51% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong profitability with a 28.56% net income margin and a 44.23% ROE for 2025. Analyst consensus is a Buy with a $95.75 price target, and institutional buying activity is evident in recent news. The stock is positioned near key resistance at $88, with support at $87.
The outlook for KO is positive, driven by consistent earnings performance and a strong dividend history, but risks include high valuation multiples and regional demand volatility. The stock offers stability with growth potential, though investors should monitor debt levels and competitive pressures in the beverage industry.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
